|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abiraterone withdrawal syndrome (AWS) is characterized by a transient decrease in the PSA after abiraterone acetate (AA) treatment discontinuation in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC).
|
31060755 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our goal was to evaluate the impact of progression type (prostate-specific antigen [PSA] only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, by performing a post-hoc analysis using data from the CATS international registry.
|
31787484 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this multicenter validation study, TTN and PSA nadir remain important prognostic markers in predicting therapeutic outcomes in Chinese men who receive chemotherapy for mCRPC.
|
31672485 |
2020 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Men with chemotherapy-naive mCRPC with a prostate-specific antigen (PSA) >10 ng/mL were eligible for enrolment.
|
30952818 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016.
|
30686756 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
|
30099821 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done at 254 study sites worldwide, patients aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned (2:1) via an interactive voice web recognition system to receive oral enzalutamide (160 mg per day) or placebo.
|
30770294 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
(3) Results: In 114 mCRPC patients with an evaluable CTC count, the CTC count was independently associated with poor progression-free survival (PFS) and overall survival (OS) in multivariable analysis with other commonly used variables associated with outcome in mCRPC (age, prostate specific antigen (PSA), alkaline phosphatase, lactate dehydrogenase (LDH), albumin, hemoglobin), together with alkaline phosphatase and hemoglobin.
|
31434336 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and at 4 and 12 weeks after initiation of abiraterone, and we evaluated prostate-specific antigen (PSA) response every 4 weeks in 102 metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone either pre- or postchemotherapy.
|
30977383 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sixty-five patients with mCRPC who were treated with enzalutamide 160 mg daily and had at least one steady-state enzalutamide plasma concentration between May 2015 and June 2018; of these patients, 38 were prostate-specific antigen (PSA) responders and 27 were nonresponders.
|
31596947 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
|
31092441 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
|
30980027 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study has demonstrated that PSA dynamics after ENZ administration may be a useful prognostic factor for mCRPC patients.
|
31334872 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
L-377,202 prodrug (Dox-PSA) was in phase I clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC).
|
30802065 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
|
30729312 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have >50% PSA remission.
|
28905815 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
|
30279582 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
|
31369101 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis showed response to first ADT ≤ 12 months, Gleason score of 8 to 10, clinical progression, and high prostate-specific antigen levels at mCRPC diagnosis were associated with worse OS.
|
29550200 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that approximately two-thirds of any PSA decline and one-third of a greater than 50% PSA decline can be expected after the first cycle of Lu-PSMA-617 radioligand therapy in patients with mCRPC.
|
30059428 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29.7) receiving <sup>223</sup>RaCl<sub>2</sub>.
|
29785515 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
|
30126765 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A poorer baseline performance status, faster disease pace measured by the PSA doubling time, and previous novel androgen signaling inhibitor exposure could be important prognostic considerations for the treatment of mCRPC patients with sipuleucel-T. Further studies are needed to validate these findings.
|
29352713 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using STRIVE data (patients with metastatic disease: n = 128 enzalutamide; n = 129 bicalutamide) comparing enzalutamide with bicalutamide at 1 and 2 years, the numbers needed to treat to achieve one additional patient with chemotherapy-naïve metastatic castration-resistant prostate cancer with progression-free survival were 2.0 and 2.8, respectively; with radiographic progression-free survival, 2.6 and 3.0, respectively; and without prostate-specific antigen progression, 1.8 and 2.4, respectively.
|
30189902 |
2018 |
|
Metastatic castration-resistant prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Single-agent prednisone for mCRPC did not improve OS but was associated with a greater PSA response rate and PFS.
|
29352714 |
2018 |